Preclinical Testing Of a Novel Axl-Kinase Inhibitor In Chronic Lymphocytic Leukemia
Maria Göbel, Michael Möllmann, André Görgens etal
Key Points:
Receptor tyrosine kinase AXL involved in progression CLL.
Two AXL inhibitors BMS777607 and LDC2636 investgated.
Elevated sAXL levels associated with shorter time to first treatment and poor prognostic factors.
Cytotoxic effects more with LDC2636 compared to BMS7777607 treated cells.
LDC2636 exhibited effects in disease relevant CLL model.
Implications:
Axl inhibitors exert potent activity against CLL cells.
Future potential treatment for CLL with less effect on normal cells.
View the original abstract on the ASH website.
